These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21321417)

  • 21. Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani.
    Corpas-Lopez V; Moniz S; Thomas M; Wall RJ; Torrie LS; Zander-Dinse D; Tinti M; Brand S; Stojanovski L; Manthri S; Hallyburton I; Zuccotto F; Wyatt PG; De Rycker M; Horn D; Ferguson MAJ; Clos J; Read KD; Fairlamb AH; Gilbert IH; Wyllie S
    ACS Infect Dis; 2019 Jan; 5(1):111-122. PubMed ID: 30380837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity.
    Nühs A; De Rycker M; Manthri S; Comer E; Scherer CA; Schreiber SL; Ioset JR; Gray DW
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004094. PubMed ID: 26407168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular targets and pathways for the treatment of visceral leishmaniasis.
    Jain V; Jain K
    Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A; Singh N; Sundar S; Singh N
    Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
    Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
    J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of in vitro method to assess different brands of anti-leishmanial drugs.
    Arora SK; Sinha R; Sehgal S
    Med Microbiol Immunol; 1991; 180(1):21-7. PubMed ID: 2056963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Road-map of pre-clinical treatment for Visceral Leishmaniasis.
    Mazire P; Agarwal V; Roy A
    Drug Dev Res; 2022 Apr; 83(2):317-327. PubMed ID: 34962315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.
    De Rycker M; Hallyburton I; Thomas J; Campbell L; Wyllie S; Joshi D; Cameron S; Gilbert IH; Wyatt PG; Frearson JA; Fairlamb AH; Gray DW
    Antimicrob Agents Chemother; 2013 Jul; 57(7):2913-22. PubMed ID: 23571538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic Clustering Analysis as a Strategy for Compound Selection in the Drug Discovery Pipeline for Leishmaniasis.
    Armitage EG; Godzien J; Peña I; López-Gonzálvez Á; Angulo S; Gradillas A; Alonso-Herranz V; Martín J; Fiandor JM; Barrett MP; Gabarro R; Barbas C
    ACS Chem Biol; 2018 May; 13(5):1361-1369. PubMed ID: 29671577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds.
    Corman HN; Shoue DA; Norris-Mullins B; Melancon BJ; Morales MA; McDowell MA
    Int J Antimicrob Agents; 2019 Oct; 54(4):496-501. PubMed ID: 31323307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
    Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis.
    Kashif M; Manna PP; Akhter Y; Alaidarous M; Rub A
    Infect Disord Drug Targets; 2017; 17(2):120-129. PubMed ID: 28034363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
    Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
    Wyllie S; Brand S; Thomas M; De Rycker M; Chung CW; Pena I; Bingham RP; Bueren-Calabuig JA; Cantizani J; Cebrian D; Craggs PD; Ferguson L; Goswami P; Hobrath J; Howe J; Jeacock L; Ko EJ; Korczynska J; MacLean L; Manthri S; Martinez MS; Mata-Cantero L; Moniz S; Nühs A; Osuna-Cabello M; Pinto E; Riley J; Robinson S; Rowland P; Simeons FRC; Shishikura Y; Spinks D; Stojanovski L; Thomas J; Thompson S; Viayna Gaza E; Wall RJ; Zuccotto F; Horn D; Ferguson MAJ; Fairlamb AH; Fiandor JM; Martin J; Gray DW; Miles TJ; Gilbert IH; Read KD; Marco M; Wyatt PG
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9318-9323. PubMed ID: 30962368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiparasitic activity of a triphenyl tin complex against Leishmania donovani.
    Raychaudhury B; Banerjee S; Gupta S; Singh RV; Datta SC
    Acta Trop; 2005 Jul; 95(1):1-8. PubMed ID: 15896700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis.
    Khanra S; Juin SK; Jawed JJ; Ghosh S; Dutta S; Nabi SA; Dash J; Dasgupta D; Majumdar S; Banerjee R
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008575. PubMed ID: 32866156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
    Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
    J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel arylimidamides for treatment of visceral leishmaniasis.
    Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
    Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.